Clinic Pathological Profile of Bilateral Breast Cancer

Case Series

Austin Surg Oncol. 2019; 4(1): 1013.

Clinic Pathological Profile of Bilateral Breast Cancer

Essam E*

Department of Surgical Oncology, Tanta Cancer Center, Egypt

*Corresponding author: Elshiekh Essam, Department of Surgical Oncology, Tanta Cancer Center, Egypt

Received: September 16, 2019; Accepted: October 22, 2019; Published: October 29, 2019

Abstract

Background: Bilateral Breast Cancer (BBC) is a rare entity, no definite guidelines in treatment depending on the diagnostic methods, nomenclatures and policies of treatment. Because the incidence of breast cancer is increasing and prognosis is improving, a growing number of women are at risk of developing bilateral disease. Bilateral Breast Cancer is either Synchronous (SBBC) when diagnosed within 6 months between the two sides and Metachronous (MBBC) when diagnosed more than 6 months.

Material and Methods: Retrospective study done at Tanta cancer center- Egypt between January 2013 to end of December 2014 to evaluate the cases of bilateral breast cancer.

Results: 46 patients were diagnosed with bilateral breast cancer out of 1454 cases with breast cancer with 3.12%, 30 cases synchronous and 16 cases metachronous, mean age of 50 years in both groups,18/46cases were premenopausal with 28/46 patients postmenopausal. SBBC group, 18/30 cases diagnosed at stage III, while in MBBC 8/16 diagnosed as stage III in primary tumor. 30/46 diagnosed by FNAC and 16/46 by true cut biopsy, 34/46 cases had infiltrating duct carcinoma. 24/46 cases treated surgically by bilateral Modified Radical Mastectomy (MRM). Most of cases are triple negative (ER, PR & her2/ neu) in 26/46.

Conclusion: BBC is an uncommon clinical entity; these patients require individualized treatment based on the tumor and treatment factors of the lesion. Optimal results can be obtained by using Multimodal Treatment approach (MDT) for BBC.

Keywords: Bilateral Breast Cancer; Synchronous Breast Cancer; Metachronous Breast Cancer; Clinicopathological Profile

Abbreviations

BBC: Bilateral Breast Cancer; SBBC: Synchronous Bilateral Breast Cancer; MBBC: Metachronous Bilateral Breast Cancer; MRM: Modified Radical Mastectomy; CBS: Conservative Breast Surgery; ER: Estrogen Receptors; PR: Progesterone Receptors; HER2: Herceptin; IDC: Infiltrating Duct Carcinoma

Introduction

Breast cancer is the most common malignancy diagnosed in female [1]. Worldwide, it was estimated that new cancer cases and cancer deaths were 1.3 million and 327,000 every year [2]. With the development of the medical technology, early detection, early diagnosis and early adequate treatment may have led to prolonged survival and improved quality of life for breast cancer patients. Nevertheless, the long-term health of these patients will become a significant public health problem because the possibility of developing second primary cancers may be on rise; Bilateral Breast Cancer (BBC) is a rare entity, as compared to unilateral breast cancer, no definite guidelines in treatment depending on the diagnostic methods, nomenclatures and policies of treatment [3]. Because the incidence of breast cancer is increasing and prognosis is improving, a growing number of women are at high risk of developing bilateral disease with little is known about incidence trends and prognostic features of bilateral breast cancer [4]. Overall the incidence of BBC is 1.4%-12% of all breast cancer reported in various studies, The incidence of Synchronous Breast Cancer (SBBC) is 0.7%-3% whereas that of Metachronous Breast Cancer is (MBBC) 5%-10% [5]. Bilateral Breast Cancer is either Synchronous (SBBC) when diagnosed within 6 months between the 2 sides and Metachronous (MBBC) when diagnosed more than 6 months between the two sides, the origin of second cancer may be metastatic spread from the primary tumor or independent primary [6]. There is a two to six fold increased risk of developing contralateral breast cancer in women with first primary as compared to the general population, there is an increasing incidence of BBC due to improved diagnostic techniques, longer survival, and patient education [7,8]. The prognosis of BBC has been reported to be worse than that of Unilateral Breast Cancer (UBC) [9,10] and the biological aspects, as well as the optimum therapy, are still remains controversialm [11,12]. The present study was done to analyze the clinicopathological characteristics and treatment outcome at a tertiary cancer center in Tanta Cancer Center in Delta of Egypt.

Materials and Methods

This is a retrospective study carried out at a tertiary cancer center, Tanta cancer center in Egyptian delta, Egypt. All patients diagnosed for breast cancer were collected from start of January 2013 till end of December 2014, they found to be 1454 Patients in the department of surgical oncology, 46 (3.12%) patients diagnosed for bilateral breast cancer and taken up for the study with treatment outcomes as well as the follow-up data were recorded. Two tumors diagnosed within an interval of 6 months was defined as SBBC whereas MBBC as second cancer diagnosed after 6 months. The analysis of patient’s characteristic including age, pre/post-menopausal status, family history of breast cancer, mode of detection, and histological features between the two breasts was done. Patients were followed up for treatment outcomes and disease recurrence. Those not on regular follow-up were contacted telephonically.

Results

During the period of start of January 2013 to the end of December 2014, total number of breast cancer diagnosed was 1454 cases, of them 46 (3.12%) patients diagnosed as Bilateral Breast Cancer (BBC), 30 (2.02%) patients diagnosed as Synchronous Breast Cancer (SBBC) while 16 (1.1%) patients diagnosed as Metachronous Bilateral Breast Cancer (MBBC), all patients diagnosed in this study are women with median age of 50years (range from 28-71) in synchronous group and (35-65) in metachronous group, 40 patients had previous breast feeding with 3 patients had positive family history of breast cancer for mothers. 6 cases diagnosed by mammographic exam and 24 cases by clinical examination in SBBC while in MBBC, 4 cases diagnosed by mammographic examination compared to 12 cases diagnosed clinically. Tumor size tend to be more larger in Synchronous than Metachronous group which start at right side in 10 cases and 6 cases started with left side with least period between the two of 12 months and longest is 108 months.

At the time of diagnosis there were 10 cases premenopausal and 20 postmenopausal at synchronous group while in metachronous group there were 8 and 8 pre and postmenopausal, average time of diagnosis of contralateral breast cancer is 5ys ranging from 12-108 months. Nine cases diagnosed with mammographic examination while 37 patients diagnosed clinically.

Pathologically 30 patients were diagnosed by FNAC 18 cases in SBBC and 12 cases in MBBC and 16 patients diagnosed with true cut needle biopsy 12 cases in SBBC and 4 cases in MBBC group, while out of 92 pathological examination there were 68 pathology diagnosed as infiltrating duct carcinoma, 12 pathology were lobular carcinoma, 4 pathology as mucoid carcinoma; 4 mixed lobular and ductal carcinoma, 4 were multifocal and duct carcinoma in situ diagnosed in 2 biopsies. Out of 92 tumors 48 tumors diagnosed at stage III while 23 tumors diagnosed as stage II and 17 diagnosed as stage IV and 4 were stage I, 26 patients were found triple negative in examination (Estrogen receptor, Progesteron receptor and Her2/neu), ER +ve, PR +ve, Her2/neu +ve and KI67 +ver were found in 14/30, 13/30, 14/30 and 24/30 in synchronous group respectively in synchronous and while 6/16, 6/16, 6/16 and 10/16 in metachronous group respectively.

In our study in synchronous group 16/30 (53.3%) cases treated with bilateral Modified Radical Mastectomy (MRM), 4/30 (13.3%) treated by bilateral Conservative Breast Surgery (CBS) and 10/30 (33.4%) cases treated with combined MRM and CBS. While in metachronous group there were 8/16 (50%) treated by bilateral MRM, 6/16 (37.5%) treated by bilateral CBS and 2/16 (12.5%) treated with MRM and CBS. The clinical, pathological and surgical treatment are present in below Table 1,2 & 3 (Figures 1 & 2).